During the screening of more than 350,000 compounds for possible efficacy in the treatment of Duchenne muscular dystrophy, researchers with the National Institutes of Health’s National Center for Advancing Translational Sciences and the University of Nevada, Reno School of Medicine identified SU9516, which had been previously used in the development of a leukemia treatment. In both laboratory and animal models, the compound generated significant improvements in muscle function.
The results of the study suggest the compound could one day be developed into a treatment for DMD and other muscle-wasting conditions.
“Our findings open the door to develop new drug treatments for DMD,” said Juan Marugan, PhD, acting branch chief of NCATS’ chemical genomics center.
More articles on quality:
100 patient safety benchmarks | 2017
Pediatric chemotherapy linked to cognitive issues later in life
AHA urges CMS: Use only quality measures that matter
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
